Inclusion Criteria:

- Patients must give their written informed consent before any procedure related to the
study is performed.

- Patients with renal clear cell carcinoma metastatic or locally advanced,
histologically or cytologically documented.The patients with metastasic disease must
be not condidated to curative nefrectomy as investigator criteria.

- Assessable or measurable disease according to RECIST criteria. The lesions previosly
radiated is not considered as target.

- Ages equal or superior to 18 years old.

- ECOG ≤ 1

- Patients with a life expectancy superior to 12 weeks.

- Patients with adequate organic function, according to the following criteria:

1. . Medular reserve: Neutrophils absolute count≥ 1.5 x 10^9/L Platelets ≥ 100 x
10^9/L Haemoglobin ≥ 9g/dl

2. . Hepatic function: Total bilirubin < 1.5 times the superior limit of normality
ALT and AST < 2.5 times the superior limit of normality (< 5 times the superior
limit of normality in case of liver failure due to cancer)

3. . Seric Albumin ≥ 1.5 times the superior limit of normality

4. . Renal Function: Cleary creatinine > 30ml/min

5. . FEVI > LIN according to ECO or MUGA

- Patients who are capable of accomplishing the study's requirements and without any
impediments to follow the instructions while on study

Exclusion Criteria:

- Pregnant or breastfeeding women. Women of fertile age must have a negative result in
the pregnancy test performed 7 days before the beginning of the administration of the
study medication. Both men and women included in the study must use an adequate
contraceptive method.

- Patients that have received sistemic treatment previous to metastasic disease.

- Previous nefrectomy.

- Mayor Surgery, radiotherapy or sistemic therapy received in the last 3 weeks previous
to the inclusion of the patient in the study, except paliative radiotherapy upper no
target lesions.

- Radiotherapy upper > 25% bone marrow.

- Patients that are participating in any clinical trial.

- Patients with a primary cancer diagnosis in thast 3 years, except superficial
basaliomas, superficial escamous carcinoma or in situ cervix carcinoma with aducuate
treatment.

- Following events in the last 12 months previous to begin the treatment: myocardial
infarction, unstable o severe angina, coronary/periferic place of arterial by-pass,
congestive cardiac insufficiency, brain-vascular accident included transitory
ischemia or lung embolism.

- Arterial uncontrolled hypertension nor controlated with drugs ( >150/100 mmHg despite
adequate medical treatment).

- Cardiac arrhythmia with grade NCI CTCAE ≥2, auricular fibrillation all grade and/or
QTc interval> 450mseg in men and > 470 mseg in women.

- Actually treatment with therapeutic dose with acenocumarol (except low dose for deep
venous thrombosis).

- Patients that present previously known positive serology for HIV.

- Abuse of substances, clinical conditions, psychological or social, that may interfere
with the patient's participation in the study or with the evaluation of the study's
results.